OR WAIT null SECS
September 30, 2021
FDA approved AbbVie’s Qulipta (atogepant) as a preventative migraine treatment.
September 29, 2021
USP is publishing the analytics-focused chapter, which considers validation activities, in advance of the official publication.
CuriRx’s CuriLytics platform is a mass spectrometry instrument that will support complex biotherapeutics development.
GeneTx Biotherapeutics and Ultragenyx Pharmaceutical announced that FDA has removed the clinical hold on GTX-102, an investigational treatment for Angelman syndrome.
KSL Biomedical announced their expansion into Canada with the acquisition of Pulse Scientific and the incorporation of KSL Biomedical Canada.
According to Charles River Laboratories, when asked how long it takes for a drug to be developed and approved for market in the United States, only 10% of 1,500 Americans polled correctly estimated that it takes between 10 and 15 years.
September 27, 2021
The lack of a new permanent commissioner has hampered FDA in articulating future priorities and pushing back against miscommunications and outside complaints.
Biosimilar approvals and the advance of biosimilar testing and production may lead to greater access to alternative therapies.
September 24, 2021
Researchers in China report test results for a microneedle patch for COVID-19 vaccine delivery.
Biden outlines a plan to end the pandemic in a virtual global conference.